3SBio Inc. announced that it has entered into an exclusive licensing deal with Alteogen Inc. for the development, manufacturing and marketing of ALT-P7, a novel antibody-drug conjugate (ADC) targeting the human epidermal growth factor receptor 2 (HER2) gene pathway for cancer in Mainland China, Hong Kong and Macau. The deal included upfront, milestone and royalty payments. This is the company's first business collaboration with Alteogen.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
185,900 KRW | +3.28% | -3.73% | +88.73% |
2023 | Alteogen Inc. Announces Clinical Trial of Tergase Showed Zero Incidence of ADA | CI |
2023 | ALTEOGEN Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+88.73% | 7.14B | |
-2.29% | 89.87B | |
-3.95% | 37.57B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B | |
-17.66% | 7.32B |
- Stock Market
- Equities
- A196170 Stock
- News ALTEOGEN Inc.
- 3SBio Inc. Enters into an Exclusive Licensing Deal with Alteogen Inc